Asker acquires Baltic medtech firm Ambercell Solutions
The acquisition expands Asker's presence in the Baltics with a supply chain platform provider. It is pending regulatory approval, expected in Q4 2026.
See the latest news and media coverage for Asker. We track all announcements, press releases, and industry mentions in real time, all in one place.
European healthcare group providing medical products and solutions
asker.comLast updated
In short: Asker acquired Labo Clinic, Med Kjemi and Ambercell and posted 18% Q2 sales growth.
The acquisition expands Asker's presence in the Baltics with a supply chain platform provider. It is pending regulatory approval, expected in Q4 2026.
The highest possible rating highlights strong governance, ethics, and carbon performance in the healthcare sector.
Net sales rose 18% to SEK 4,686m, margin improved to 10.0%, and M&A pipeline remains strong.
Founded in 1978, the Irish distributor had 9 employees and SEK 73m revenue, complementing HSL Group's surgical products.
The OMXS30 index dropped 1.3 percent at the close. The commodity sector lagged while technology grew stronger.
DNB Carnegie has downgraded the recommendation on Asker from buy to sell, setting its target price at 60 SEK, compared to 105 SEK...
The shares of medical technology company Asker Healthcare Group fell by approximately 20% this Friday, after DNB Carnegie downgraded its recommendation to...
The acquisition spree continues for Asker Healthcare Group, with Med Kjemi as the latest purchase.
Track Asker and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Asker and other trending companies.